| __timestamp | Eli Lilly and Company | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 79383000 |
| Thursday, January 1, 2015 | 6533000000 | 108402000 |
| Friday, January 1, 2016 | 6452000000 | 46928000 |
| Sunday, January 1, 2017 | 6588100000 | 74959000 |
| Monday, January 1, 2018 | 5975100000 | 79716000 |
| Tuesday, January 1, 2019 | 6213800000 | 74669000 |
| Wednesday, January 1, 2020 | 6121200000 | 59040000 |
| Friday, January 1, 2021 | 6431600000 | 77417000 |
| Saturday, January 1, 2022 | 6440400000 | 91473000 |
| Sunday, January 1, 2023 | 6941200000 | 94314000 |
| Monday, January 1, 2024 | 8593800000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and MannKind Corporation have shown contrasting approaches to handling these costs. From 2014 to 2023, Eli Lilly's SG&A expenses have consistently been higher, averaging around $6.4 billion annually. In contrast, MannKind's expenses have been significantly lower, averaging approximately $78 million per year.
Despite the stark difference in absolute numbers, the trend in SG&A expenses reveals interesting insights. Eli Lilly's expenses have grown by about 5% over the decade, while MannKind's have fluctuated, peaking in 2015 and 2023. This suggests that while Eli Lilly maintains a steady increase, MannKind's cost management is more volatile. Understanding these trends can provide valuable insights into each company's strategic priorities and operational efficiencies.
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sanofi vs MannKind Corporation
Biogen Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation
Summit Therapeutics Inc. or MannKind Corporation: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights